Home >> Marketplace Archives >> StatStrip cleared for capillary testing
with critically ill

StatStrip cleared for capillary testing
with critically ill

Print Friendly, PDF & Email

October 2018—Nova Biomedical’s StatStrip Glucose Hospital Meter System has been cleared by the FDA for fingerstick capillary testing with critically ill patients. The FDA granted this 510(k) clearance to StatStrip after extensive prospective and retrospective studies were performed at the Mayo Clinic, Rochester, Minn., and Johns Hopkins Bayview Medical Center, Baltimore. The submission data comprised 16,778 patients ranging from one month to 106 years old who were receiving intensive medical intervention/therapy in critical and intensive care settings including burn, cardiac, medical, orthopedic, neurological, and surgical. StatStrip’s capillary results were equivalent to the arterial and venous plasma results measured on a central laboratory IDMS traceable reference method.

Nova Biomedical, 781-894-0800


Check Also

Glucose meter cleared for ICU, 8/15

The FDA has cleared Nova Biomedical’s StatStrip Xpress Glucose Hospital Meter System for use throughout all hospital and all professional health care settings, including among critically ill patients. StatStrip Glucose and StatStrip Xpress Glucose are, at press time, the only two hospital blood glucose meters to be cleared by the FDA for use with critically ill patients. StatStrip Xpress Glucose uses the same test strip measurement technology as StatStrip Glucose, which was cleared in 2014 after a four-year study conducted at five university medical centers.